Shares of Jasper Therapeutics jumped after the company disclosed what it called positive preliminary clinical data from an early-stage trial of its drug to treat asthma. The stock climbed 34%, to ...

Phase 3b WAYFINDER data show tezepelumab oral corticosteroid reduction in severe asthma, with nearly 90 percent reaching 5 mg ...

Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a ...

Over half of patients with severe asthma discontinued oral corticosteroids while maintaining disease control, major study ...

Monthly Tezepelumab injections helped 90% of severe asthma patients cut steroid use, with many seeing improved symptoms and ...

A monthly injection has helped 90% of severe asthma patients reduce daily steroid tablets, which are associated with ...

The use of clinical guidelines for the management of asthma can help improve patient outcomes and control costs. This article explores ways that managed care organizations can encourage physicians to ...

The new asthma treatment that could ‘transform lives’ - The injection is recommended as an additional maintenance treatment ...

Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...

Small airway dysfunction is common in adult well-controlled asthma and is independently linked to increased risk for future exacerbations.

Over the past few weeks in Victoria and other parts of Australia, we've been seeing some wild and stormy weather.

Inhaled corticosteroids are used by millions of asthma patients every day. However, as with all treatments to control asthma, there is marked patient-to-patient variability in the response to ...